Perioperative considerations for elective surgery in patients with deep brain stimulation implantation

Article information

J Korean Soc Ster Func Neurosurg. 2022;18(1):1-8
Publication date (electronic) : 2022 June 8
doi : https://doi.org/10.52662/jksfn.2022.00157
1Department of Neurosurgery, Soonchunhyang University Seoul Hospital, Seoul, Korea
2Department of Neurosurgery and Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea
3Ischemic/Hypoxic Disease Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
4Advanced Institutes of Convergence Technology, Suwon, Korea
Address for correspondence: Sun Ha Paek, MD Department of Neurosurgery, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea Tel: +82-2-2072-2350 Fax: +82-2-744-8459 E-mail: paeksh@snu.ac.kr
Received 2022 April 30; Revised 2022 May 16; Accepted 2022 May 18.

Abstract

In the more than 30 years that have passed since its introduction, deep brain stimulation (DBS) has been shown to be effective and safe for a growing number of diseases, such as depression and obsessive-compulsive disorder, as well as movement disorders such as Parkinson’s disease, dystonia, and essential tremor. As a result of population aging due to the increase in life expectancy, the number of patients requiring DBS implantation is increasing. These patients often require surgery or treatment for diseases other than the original disease that required DBS. Most diagnostic tests or procedures can damage the DBS system by various mechanisms, so clinicians unfamiliar with DBS have difficulty treating these patients. The purpose of this review is to summarize the knowledge necessary for patient management that will be useful for clinicians treating patients with DBS implantation.

BACKGROUND

Since the introduction of high-frequency unilateral thalamic stimulation by Benabid et al. [1] in 1987, the use of deep brain stimulation (DBS) has become the basis for the treatment of movement disorders refractory to medical management. The identification of the role of the subtahalamic nucleus (STN) and the introduction of the first stimulation of the STN in 1993 marked another milestone in the role of DBS in Parkinson’s disease (PD) [2,3]. Over conventional ablative treatment such as thalamotomy and pallidotomy, DBS has advantages in reversibility, adjustability and safety profile. DBS has been considered as the primary surgical treatment for movement disorders as an alternative to ablative surgery. Long-term outcomes of DBS for PD demonstrated significant improvements in quality of life and activities of daily living, as well as in basic dopamine-responsive motor and nonmotor features [4-6]. The application of DBS continues to expand, and it was approved by the United States Food and Drug Administration for dystonia in 2003 and obsessive-compulsive disorder in 2005. Recent studies have also demonstrated the efficacy and safety of DBS for pain, epilepsy, and Tourette’s syndrome [7,8]. Studies are ongoing into the role of DBS in a variety of conditions, including major depression, anorexia nervosa, and Alzheimer’s disease [9-11].

Over the past 30 years since its introduction, more than 150,000 patients worldwide have been treated with DBS [12]. Also, due to the aging of the population, by 2040, 25% of the world’s population is expected to be 65 years or older. The number of patients who received DBS implantation will continue to increase due to the increase in the elderly population, the expansion of diseases that are indications for DBS, and the discovery of new targets. When these patients require treatment for other diseases, patient management can be complicated for clinicians unfamiliar with DBS [13].

Aim of this review

Patients with DBS implantation may require treatment for other diseases, but treatment may be limited because of the presence of the DBS system. DBS-related issues should be considered when considering treatment or surgery for other conditions. The purpose of this review is to summarize the knowledges necessary for patient management useful to clinicians treating patients with DBS implantation.

This article does not include any personal data. This article was exempt from IRB approval.

DEEP BRAIN STIMULATION SYSTEM

Current DBS systems consist of unilateral or bilateral intracranial electrodes, an implantable pulse generator (IPG) under the clavicle or axilla, and an extension wire connecting the electrodes to the IPG. The system delivers stimulation to the electrodes with an amplitude, pulse width, and frequency set by the clinician and the patient’s programming device.

Although DBS systems may look similar to the well-known implantable cardiac electronic devices (CIEDs) such as pacemakers and implanted defibrillators, they differ in mechanism of action, stimulation parameter, and method of operation. The CIEDs are usually more complex to neurostimulation system including DBS. Whereas program parameters are adjusted based on electrical feedback from the leads in CIEDs, neurostimulator provides continuous stimulation on the target region. As for stimulation parameter, neurostimulation uses higher frequency above 100 Hz and higher current, CIEDs uses lower frequency and lower current. DBS system can be turned off, but CIEDs cannot be turned off. In both systems, the function may be impaired by electromagnetic interference, which may lead to patient morbidity.

Previous DBS systems delivered current in a voltage controlled method by electrochemically induced changes in electrode impedance at the brain-electrode interface [14]. Current systems provide a more clinically effective constant current stimulation by current-controlled method [15]. DBS systems provide either unipolar or bipolar stimulation. In unipolar mode, the active electrode is set to the cathode and the IPG case is set to the anode. In bipolar stimulation, one of the four electrodes of the electrode acts as the cathode and the other acts as the anode. Modern DBS systems provide a rechargeable IPG, which extends the life of the device and reduces the need for additional surgery to replace the IPG [16,17].

MEDICAL IMAGING

X-ray, diagnostic ultrasound and computed tomography

Patients who have DBS systems can safely undergo x-ray, diagnostic sonographic ultrasound, and computed tomography (CT) scans without additional management.

Magnetic resonance imaging

Magnetic resonance imaging (MRI) imaging of patients with DBS systems was previously absolutely contraindicated due to electromagnetic interactions. Problems caused by electromagnetic interactions include excessive heating of the DBS electrode tip due to the synthesis of the generated current, voltage induction proportional to the gradient pulse change over time, unintentional reprogramming of the IPG, image artifacts and distortion, and the functioning of the DBS system [18]. The amount of heat generated within a DBS system by electromagnetic interaction depends on several factors such as the electrical properties of the stimulator, the field strength of the MRI system, the location of the DBS component relative to the radiofrequency (RF) energy source, the RF coil used, the imaging site, and the specific absorption rate [19].

DBS manufacturers provide specific guidelines for the use of MRI in patients with DBS implantation. Boston Scientific has previously banned MRI scans after DBS, but states that the new system is only possible with a 1.5 T full body or head transmit/receive and RF quadrature only coil [20]. Medtronic also states that patients with DBS system can undergo MRI scans under specific conditions, and complete MRI guideline is available from their website (https://manuals.medtronic.com/manuals/mri/region) [21].

In situations where MRI cannot be replaced with CT or ultrasound, clinicians should always confirm with manufacture and check the following conditions prior to MRI scan (Table 1). Table 2 presents points to be noted before, during, and after MRI.

Specific conditions to check prior to MRI scans in patients with a DBS system

Specific considerations before, during, and after MRI scans

INTRAOPERATIVE CONSIDERATION – MEDICAL DEVICE INTERACTIONS WITH THE DEEP BRAIN STIMULATION SYSTEM

Several medical devices used during surgery can interact with the DBS system, generating varying degrees of electromagnetic interference, potentially affecting the functioning of the neurostimulator. Even with the DBS system turned off, the conductivity of the metal case, leads and DBS device is maintained and current can pass through it.

Diathermy

Diathermy refers to the treatment via heat, with the generation of heat within body tissues from high-frequency electromagnetic currents to promote healing or aid in healing (Fig. 1A). In principle, it is applied transdermally and electrically generates a shortwave diathermy with a power of up to 1,000 W. It is often used to relax muscle and treat joint disorders [22].

Fig. 1.

Examples of medical devices that may affect the deep brain stimulation system. (A) Diathermy. (B) Electrocautery. (C) Electrosurgery.

There have been case reports of serious brain damage due to heat generation at the tip of the DBS electrodes after using diathermy for dental treatment [23,24]. Manufacturers have since issued a product advisory advising caution against the use of all forms of diathermy in patients with neurostimulators [16,17].

Electrocautery

Electrocautery is a treatment in which heat is generated within a metal wire electrode by passing an electric current, typically used for tissue destruction to varying degrees, such as tissue hemostasis or removal of benign skin lesions (Fig. 1B). None of the manufacturer’s safety reports state things with electrocautery, and the Medtronic guidelines group them together as “diathermy” and into a possible hazard category [25].

The effect of electrocautery on cardiac pacemaker has been widely reported, and the effect on DBS can be estimated based on it. Cases of pacemaker failure due to electrocautery in an asynchronous mode resulting in hemodynamic instability have been reported [26]. Unintended reprogramming can occur even in asynchronous mode when used very close to the IPG [27,28]. Caution is needed when used very close to the IPG, because unintended reprogramming can occur even in asynchronous mode.

Electrosurgery

Electrosurgery is generally used during surgery and includes various methods of cutting and coagulation as electrical energy flows from an active electrode to a distributed electrode (Fig. 1C) [22]. Electrosurgery affects the tissue immediately adjacent to the active electrode. There are two different electrode configurations: unipolar mode and bipolar mode.

Unipolar mode

In the unipolar mode, a current generated through an electrode enters the patient’s body and reaches a grounding pad. The presence of a conductive material between the monopolar device and the dispersive pad can redirect the path, which may inadvertently heat the tissue outside the surgical target due to the conversion of current to heat as energy passes through the tissue. Unipolar electrosurgery can induce thermal brain injury in patients with DBS system, so its use is not recommended by all DBS manufacturers. However, unlike diathermy, there are no experimental works or clinical trials for the use of electrosurgery.

Sometimes the surgeon may inevitably have to use monopole cauterization. In such a situation, the ground plane may be placed on the shoulder or occiput opposite the IPG [29]. The DBS system should be switched off and used at the lowest possible energy level.

Bipolar mode

In bipolar mode, the current only passes through the tissue between the two electrodes of the electrosurgical device, so the current spread is small. The bipolar mode of electrosurgery can be safely used in patients with implanted neurostimulators [30].

Electrocardiogram

Electrical signals generated by the DBS system may affect the electrocardiogram (ECG) recording, so may need to be turned off to limit interference [31]. However, it should be kept in mind that turning off the DBS unit may result in recurrent motor symptoms, resulting in artifacts interfering with ECG recording.

Postoperative considerations

After the operation, the DBS system must be turned on again. In the case of general anesthesia, the recurrence of motor symptoms can be prevented by turning on the device before waking up from anesthesia [30,32]. Because the extrathalamic arousal system is involved in the human sleep-wake cycle, STN stimulation can result in cortical asrousal [32].

MEDICATIONS TO AVOID

The most frequent disease for which patients underwent DBS surgery is PD, and antidopaminergic drugs such as metoclopramide and dopamine depleting drugs should be avoided to avoid worsening symptoms [33]. Comprehensive drug adjustment is required so that the combination drug does not aggravate symptoms or cause serious side effects due to drug interactions in consideration of comorbidities. Tricyclic antidepressants for pain control can cause hypertensive crisis and dyskinesia when taken together with levodopa. Antipsychotic drugs, such as phenothiazine, should be avoided as they can worsen PD-related symptoms.

ADDITIONAL TREATMENT METHODS

Ultrasound

Although diagnostic ultrasound can be safely performed in patients with an implanted nerve stimulator, the manufacturer recommends not placing the transducer directly over the implanted device. Therapeutic ultrasound depends on the output. There have been case reports that phacoemulsification for cataract removal was safely performed in patients with DBS [34,35]. However, lithotripsy can damage the neurostimulator circuit due to high-power ultrasound frequencies. This does not mean that the use of lithotripsy is contraindicated in patients with DBS, but if it is unavoidable, the ultrasound beam should not be directed within 15 cm of the neurostimulator [36]. MRI-guided focused ultrasound, which has been widely used recently for essential tremor, is, in principle, a contraindicated treatment when metallic substances such as neurostimulators and pacemakers exist in the body [37].

Radiation therapy

The risk to the DBS system of radiation therapy can be assessed on the basis of reports of patients with CIED. In vivo and in vitro studies, ionizing radiation has been shown to affect voltage changes by causing permanent and/or potential damage due to ionization of semiconductors in circuits [38,39]. Radiation therapy should not be administered near DBS devices, as irradiation may induce the creation of abnormal electrical pathways. If radiation therapy is required, lead shielding should be used to limit exposure and to protect the device, and the device should be checked for defects after each session [36,40]. In such situations, guidance on the safe application of radiation therapy for patients using CIEDs may be consulted [41,42]. Table 3 represents the risk classification of patients with CIEDs according to the cumulative dose and pacing dependence [41]. Using energies greater than 10 Gy can damage the random access memory and semiconductors in the device due to secondary neutrons generated in the linear accelerator head [43].

Risk classification of patients with CIEDs according to the cumulative dose and pacing dependence

Laser

Because there are limited data on the safety of the laser use in patients with DBS, caution should be exercised prior to use and the risks should be fully discussed with the patient. When performing laser treatment, the DBS system should be turned off and the laser should be placed as far away from the system as possible [36]. After treatment, the DBS unit should be checked.

External cardiac defibrillators

Since external cardiac defibrillation and cardioversion are required for lifesaving purpose in emergent situations, its use should not be withheld in patients with DBS. There has been case report that 300 J of external cardioversion did not affect the DBS system [44]. Medtronic recommends using the lowest possible power setting and placing the paddle perpendicular to the DBS system as far from the neurostimulator as possible [36].

Electroconvulsive therapy

When electroconvulsive therapy (ECT) is required in a patient implanted with DBS, safety concerns from heat generation at the DBS electrode due to induction of RF current by electric charge, functional disruption of the DBS system, and electrode displacement due to induced seizure activity should be considered. There have been case reports in which ECT was safely performed with the nerve stimulator turned off, the ECT electrode placed as far from the DBS electrode as possible, and using the lowest possible energy to induce seizures [45,46].

Cardiac pacemakers and implantable cardioverter defibrillators

The implantation of pacemakers and/or implantable cardioverter defibrillators (ICDs) in patients using neurostimulators is not contraindicated. However, it requires the approach of a multidisciplinary team (e.g., cardiologist, DBS specialist, anesthesiologist) to optimize the patient’s clinical condition and adjust the settings of the underlying medical device as needed. Measures are needed to prevent potential interactions between devices. The pacemaker should be programmed for bipolar detection mode to avoid over-exaggeration and inappropriate response [47,48]. It is not recommended to insert the IPGs of the two systems in close proximity to reduce electromagnetic interference [47]. After the ICD delivers the shock, the function of the nerve stimulator should be checked. To ensure consistent functioning of the pacemaker device, detailed cardiac investigations such as Holter monitoring should be performed whenever DBS device settings are adjusted [49].

Physical therapy

One of the things to be aware of when doing physical therapy in patients with DBS is Twiddler syndrome, which is a malfunction of the device due to damage to the IPG or lead [50]. Lead dislodgment, diaphragmatic stimulation, and loss of capture may occur due to conscious or unconscious manipulation of the implantation site, leading to device malfunction. X-ray examination should be performed before treatment to confirm the position of the lead and IPG (Fig. 2), and caution is required as the wire may be damaged by neck manipulation at a large angle.

Fig. 2.

Example of Twiddler syndrome, which is a malfunction of the device due to damage to the implantable pulse generator or lead.

Mammography

Caution is required as overclocking may cause physical damage to the DBS device if the tissue is compressed too hard during mammography.

Summary

· X-rays, CT, and diagnostic ultrasound can be done relatively safely.

· If MRI cannot be substituted for other tests, it should be performed according to the recommendations by referring to the manufacturer’s guideline.

· The DBS system can interact with other medical device used during surgery by electromagnetic interference.

· If electrosurgery is required during surgery for hemostasis, use bipolar mode instead of unipolar mode.

· High-power ultrasound for therapeutic purpose should be avoided as much as possible. If absolutely necessary, make sure that the beam does not enter within 15 cm of the system.

· Radiation therapy using energy of 10 Gy or more can damage the DBS system.

CONCLUSION

Clinicians who manage patients with DBS should always pay attention to the device, and keep in mind that device can be damaged during procedure or surgery. A multidisciplinary approach involving DBS experts is often required. The DBS system should be reassessed to confirm if it works well.

Notes

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

References

1. Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 1987;50:344–6.
2. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366–75.
3. Pollak P, Benabid AL, Gross C, Gao DM, Laurent A, Benazzouz A, et al. Effets de la stimulation du noyau sous-thalamique dans la maladie de Parkinson [Effects of the stimulation of the subthalamic nucleus in Parkinson disease]. Rev Neurol (Paris) 1993;149:175–6. French.
4. Weaver FM, Follett KA, Stern M, Luo P, Harris CL, Hur K, et al, ; CSP 468 Study Group. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology 2012;79:55–65.
5. Castrioto A, Lozano AM, Poon YY, Lang AE, Fallis M, Moro E. Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol 2011;68:1550–6.
6. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 2003;349:1925–34.
7. Pereira EA, Green AL, Aziz TZ. Chapter 23 - Deep brain stimulation for pain. Handb Clin Neurol 2013;116:277–94.
8. Krack P, Volkmann J, Tinkhauser G, Deuschl G. Deep brain stimulation in movement disorders: from experimental surgery to evidence-based therapy. Mov Disord 2019;34:1795–810.
9. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005;45:651–60.
10. Sobstyl M, Stapińska-Syniec A, Sokół-Szawłowska M, Kupryjaniuk A. Deep brain stimulation for the treatment of severe intractable anorexia nervosa. Br J Neurosurg 2019;33:601–7.
11. Lv Q, Du A, Wei W, Li Y, Liu G, Wang XP. Deep brain stimulation: a potential treatment for dementia in Alzheimer’s disease (AD) and Parkinson’s disease dementia (PDD). Front Neurosci 2018;12:360.
12. Hariz M. My 25 stimulating years with DBS in Parkinson’s disease. J Parkinsons Dis 2017;7:S33–41.
13. Zhang J, Wang T, Zhang CC, Zeljic K, Zhan S, Sun BM, et al. The safety issues and hardware-related complications of deep brain stimulation therapy: a single-center retrospective analysis of 478 patients with Parkinson’s disease. Clin Interv Aging 2017;12:923–8.
14. Miocinovic S, Lempka SF, Russo GS, Maks CB, Butson CR, Sakaie KE, et al. Experimental and theoretical characterization of the voltage distribution generated by deep brain stimulation. Exp Neurol 2009;216:166–76.
15. Lempka SF, Johnson MD, Miocinovic S, Vitek JL, McIntyre CC. Current-controlled deep brain stimulation reduces in vivo voltage fluctuations observed during voltage-controlled stimulation. Clin Neurophysiol 2010;121:2128–33.
16. Medtronic. Deep Brain Stimulation for Movement Disorders. Medtronic for Healthcare Professionals [Internet]. Dublin: Medtronic; cited 2016. Available from: https://www.medtronic.com/us-en/healthcare-professionals/therapies-procedures/neurological/deep-brain-stimulation/indications-safety-warnings.html.
17. Boston Scientific. VerciseTM DBS System [Internet]. Marlborough: Boston Scientific; cited 2016. Available from: https://www.bostonscientific.com/en-US/products/deep-brain-stimulation-systems/vercise-genus-dbs-system-indications-safety-and-warning.html.
18. Finelli DA, Rezai AR, Ruggieri PM, Tkach JA, Nyenhuis JA, Hrdlicka G, et al. MR imaging-related heating of deep brain stimulation electrodes: in vitro study. AJNR Am J Neuroradiol 2002;23:1795–802.
19. Rezai AR, Phillips M, Baker KB, Sharan AD, Nyenhuis J, Tkach J, et al. Neurostimulation system used for deep brain stimulation (DBS): MR safety issues and implications of failing to follow safety recommendations. Invest Radiol 2004;39:300–3.
20. Boston Scientific. ImageReady MRITM Guidelines for Boston Scientific Deep Brain Stimulation Systems [Internet]. Marlborough: Boston Scientific; cited 2019. Available from: https://www.bostonscientific.com/content/dam/Manuals/us/current-rev-en/92195369-01_ImageReady%E2%84%A2_MRI_Guidelines_for_Boston_Scientific_Deep_Brain_Stimulation_Systems_en-US_s.pdf.
21. Medtronic. Lead Kit for Deep Brain Stimulation, 3387, 3389, Implant Manual. Minneapolis : Medtronic, 2002.
22. Riordan AT, Gamache C, Fosko SW. Electrosurgery and cardiac devices. J Am Acad Dermatol 1997;37:250–5.
23. Nutt JG, Anderson VC, Peacock JH, Hammerstad JP, Burchiel KJ. DBS and diathermy interaction induces severe CNS damage. Neurology 2001;56:1384–6.
24. Ruggera PS, Witters DM, von Maltzahn G, Bassen HI. In vitro assessment of tissue heating near metallic medical implants by exposure to pulsed radio frequency diathermy. Phys Med Biol 2003;48:2919–28.
25. Medtronic. Electrocautery/Surgery Standard Letter. Dublin : Medtronic, 2014.
26. Senthuran S, Toff WD, Vuylsteke A, Solesbury PM, Menon DK. Editorial III: implanted cardiac pacemakers and defibrillators in anaesthetic practice. Br J Anaesth 2002;88:627–31.
27. Mangar D, Atlas GM, Kane PB. Electrocautery-induced pacemaker malfunction during surgery. Can J Anaesth 1991;38:616–8.
28. Domino KB, Smith TC. Electrocautery-induced reprogramming of a pacemaker using a precordial magnet. Anesth Analg 1983;62:609–12.
29. American Society of Anesthesiologists. Practice advisory for the perioperative management of patients with cardiac implantable electronic devices: pacemakers and implantable cardioverter-defibrillators: an updated report by the american society of anesthesiologists task force on perioperative management of patients with cardiac implantable electronic devices. Anesthesiology 2011;114:247–61.
30. Khetarpal M, Yadav M, Kulkarni D, Gopinath R. Anaesthetic management of a patient with deep brain stimulation implant for radical nephrectomy. Indian J Anaesth 2014;58:461–3.
31. Martin WA, Camenzind E, Burkhard PR. ECG artifact due to deep brain stimulation. Lancet 2003;361:1431.
32. Singh M, Venkatraghavan L. Cortical arousal with deep brain stimulation after general anesthesia for laparoscopic cholecystectomy. J Neurosurg Anesthesiol 2018;30:77–8.
33. National Center for Biotechnology Information. PubChem Compound Summary for CID 6047, Levodopa [Internet]. Bethesda: National Center for Biotechnology Information; cited 2022 Apr 29. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Levodopa.
34. Parsloe CF, Twomey JM. Safety of phacoemulsification in a patient with an implanted deep brain neurostimulation device. Br J Ophthalmol 2005;89:1370–1.
35. Ozturk F, Osher RH. Phacoemulsification in a patient with a deep brain stimulator. J Cataract Refract Surg 2006;32:687–8.
36. Medtronic. DBS Therapy - Information for Prescribers [Internet]. Minneapolis: Medtronic; cited 2016. Available from: https://www.medtronic.com/us-en/businesses/restorative-therapies-group.html.
37. INSIGHTEC. Safety Information [Internet]. Tirat Carmel: INSIGHTEC; cited 2022 Apr 29. Available from: https://insightec.com/safety-information/.
38. Hashii H, Hashimoto T, Okawa A, Shida K, Isobe T, Hanmura M, et al. Comparison of the effects of high-energy photon beam irradiation (10 and 18 MV) on 2 types of implantable cardioverter-defibrillators. Int J Radiat Oncol Biol Phys 2013;85:840–5.
39. Elders J, Kunze-Busch M, Smeenk RJ, Smeets JL. High incidence of implantable cardioverter defibrillator malfunctions during radiation therapy: neutrons as a probable cause of soft errors. Europace 2013;15:60–5.
40. Medtronic. Frequently Asked Questions [Internet]. Dublin: Medtronic; cited 2016. Available from: http://www.medtronicneuro.com.au/faq_pain_neurostimulation.
41. Gauter-Fleckenstein B, Israel CW, Dorenkamp M, Dunst J, Roser M, Schimpf R, et al, ; DEGRO/DGK. DEGRO/DGK guideline for radiotherapy in patients with cardiac implantable electronic devices. Strahlenther Onkol 2015;191:393–404.
42. Tajstra M, Gadula-Gacek E, Buchta P, Blamek S, Gasior M, Kosiuk J. Effect of therapeutic ionizing radiation on implantable electronic devices: systematic review and practical guidance. J Cardiovasc Electrophysiol 2016;27:1247–51.
43. Hashimoto T, Isobe T, Hashii H, Kumada H, Tada H, Okumura T, et al. Influence of secondary neutrons induced by proton radiotherapy for cancer patients with implantable cardioverter defibrillators. Radiat Oncol 2012;7:10.
44. Rosenow JM, Tarkin H, Zias E, Sorbera C, Mogilner A. Simultaneous use of bilateral subthalamic nucleus stimulators and an implantable cardiac defibrillator. Case report. J Neurosurg 2003;99:167–9.
45. Moscarillo FM, Annunziata CM. ECT in a patient with a deep brain-stimulating electrode in place. J ECT 2000;16:287–90.
46. Chou KL, Hurtig HI, Jaggi JL, Baltuch GH, Pelchat RJ, Weintraub D. Electroconvulsive therapy for depression in a Parkinson’s disease patient with bilateral subthalamic nucleus deep brain stimulators. Parkinsonism Relat Disord 2005;11:403–6.
47. Capelle HH, Simpson RK Jr, Kronenbuerger M, Michaelsen J, Tronnier V, Krauss JK. Long-term deep brain stimulation in elderly patients with cardiac pacemakers. J Neurosurg 2005;102:53–9.
48. Ozben B, Bilge AK, Yilmaz E, Adalet K. Implantation of a permanent pacemaker in a patient with severe Parkinson’s disease and a preexisting bilateral deep brain stimulator. Int Heart J 2006;47:803–10.
49. Obwegeser AA, Uitti RJ, Turk MF, Wszolek UM, Flipse TR, Smallridge RC, et al. Simultaneous thalamic deep brain stimulation and implantable cardioverter-defibrillator. Mayo Clin Proc 2001;76:87–9.
50. Doyle SR, Kremer MJ. AANA journal course. Update for nurse anesthetists. Parkinson disease. AANA J 2003;71:229–34.

Article information Continued

Fig. 1.

Examples of medical devices that may affect the deep brain stimulation system. (A) Diathermy. (B) Electrocautery. (C) Electrosurgery.

Fig. 2.

Example of Twiddler syndrome, which is a malfunction of the device due to damage to the implantable pulse generator or lead.

Table 1.

Specific conditions to check prior to MRI scans in patients with a DBS system

Checklists prior to MRI scans in patients with a DBS system
• Only 1.5-T horizontal-bore MRI
• Only a transmit/receive head coil
• Calculation of the head SAR using correct patient weight
• MRI parameters that allow an average head SAR≤0.1 W/kg
• The gradient dB/dt≤20 T/s [32]

MRI: magnetic resonance imaging, DBS: deep brain stimulation, SAR: specific absorption rate.

Table 2.

Specific considerations before, during, and after MRI scans

Before MRI Identify the implanted DBS system
 The model of the implanted DBS system
 The presence of an implanted pocket adaptor
 Implant status of the lead
 Integrity of the system in terms of any suspicious wire breaks
Check for MRI contraindications
 Receiver-only coil applied to the head or a transmission coil extending above the chest
 Evidence of electrode or connecting wire breaks
 Use of non-compliant parameters
 Availability of safer diagnostic methods (e.g., computed tomography or sonography)
 Other implants or limiting factors for which MRI is prohibited or contraindicated
Check the impedance of all electrodes and the battery voltage
Record the stimulation values
Turn off the neurostimulator
 Set the stimulation amplitude to 0 V
Check the use of the appropriate MRI parameters
Limit the active scan time
Provide a sufficient explanation to the patient about possible complications and ask the patient to report any discomfort
Properly position the patient
During MRI Avoid sedation for constant communication with the patient to identify early complications
 Warming sensation, pain, unpleasant stimulation, unusual sensations
Perform continuous patient monitoring
Check consciousness between MRI sequences
After MRI Confirm the patient’s condition
Have a DBS specialist check whether the stimulator is working
Turn on the device and reprogram the stimulator to its original settings

MRI: magnetic resonance imaging, DBS: deep brain stimulation.

Table 3.

Risk classification of patients with CIEDs according to the cumulative dose and pacing dependence

<2 Gy 2–10 Gy >10 Gy
Device-independent Low risk Intermediate risk High risk
Device-dependent Intermediate risk High risk High risk

CIED: implantable cardiac electronic device.